SCHEMBL3340328

SCHEMBL3340328

COc1ccc2c(C)nnc(Nc3ccc4c(c3)ncn4-c3ccccc3)c2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 6/20 0.60
GAA P10253 3/20 0.57
KDR P35968 1/20 0.53
ALDH1A1 P00352 5/20 0.52
HPGD P15428 5/20 0.52
MAPT P10636 5/20 0.52
HTT P42858 3/20 0.52
LMNA P02545 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
MAPK1 P28482 1/20 0.51
MAPK10 P53779 1/20 0.51
NCOA1 Q15788 1/20 0.51
NCOA3 Q9Y6Q9 1/20 0.51
NPC1 O15118 3/20 0.49
RAB9A P51151 2/20 0.49
AKR1C3 P42330 1/20 0.49
KIT P10721 1/20 0.47
FLT3 P36888 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
ALOX12 P18054 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2307301 0.96 FGFR1 (0.60) FGFR1GAAKDRALDH1A1HPGD
SCHEMBL3342348 0.90 GAA (0.65) FGFR1GAAKDRALDH1A1HPGD
SCHEMBL12135737 0.89 GAA (0.64) FGFR1GAAKDRALDH1A1HPGD
SCHEMBL2308834 0.88 GAA (0.52) FGFR1GAAKDRALDH1A1HPGD
SCHEMBL2308483 0.88 GAA (0.73) FGFR1GAAALDH1A1HPGDMAPT
Hydrochloric Acid SCHEMBL2309577 0.87 GAA (0.71) FGFR1GAAALDH1A1HPGDMAPT
SCHEMBL13304851 0.86 GAA (0.59) FGFR1GAAALDH1A1HPGDMAPT
SCHEMBL2305621 0.84 GAA (0.52) FGFR1GAAKDRALDH1A1HPGD
SCHEMBL13304855 0.82 GAA (0.59) FGFR1GAAALDH1A1HPGDMAPT
SCHEMBL13304847 0.82 GAA (0.67) FGFR1GAAKDRALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012217-B2 Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2015-04-21 US disclosed
US-9012217-B2 Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2015-04-21 US disclosed
US-9012217-B2 Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2015-04-21 US disclosed
US-20100159596-A1 SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-06-24 US disclosed
US-20100159596-A1 SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-06-24 US disclosed
US-20100159596-A1 SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100159596-A1 SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION RCOR3, BRD3, BRPF3 FGFR1 102/4885GAA 4544/4885KDR 2632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.